SNAKEBITE ENVENOMATION QUICK GUIDE TO USING THE NEW SNAKEBITE CPG BACKGROUND GENERAL PRINCIPLES OF SNAKEBITE MANAGEMENT WHO SHOULD CARRY ANTIVENOM & UNDER WHAT CIRCUMSTANCES? NON-FDA APPROVED ANTIVENOMS RECOMMENDED IN THIS CPG UNIVERSAL APPROACH TO THE SNAKEBITE PATIENT SYSTEMIC INSTABILITY & SUDDEN COLLAPSE SYNDROME DEFINING CLINICAL SNAKEBITE SYNDROMES, SEVERITY, & INITIAL CONTROL QUICK GUIDE TO ANTIVENOM ADMINISTRATION ADJUNCT TREATMENTS, SUPPORTIVE CARE, ONGOING MONITORING, AND ADDITIONAL ANTIVENOM DOSES ADVERSE REACTIONS TO ANTIVENOM ADVERSE REACTIONS TO ANTIVENOM: TREATMENT SPECIAL SITUATIONS OCULAR ENVENOMATION BY SPITTING COBRAS (VENOM OPTHALMIA) RISKS OF NON-RECOMMENDED ANTIVENOMS & LOCAL PROCUREMENT PERFORMANCE IMPROVEMENT (PI) MONITORING REGIONALLY SPECIFIC SNAKEBITE TREATMENT SECTIONS APPENDIX A: STAT TREATMENT ALGORITHMS APPENDIX B: AFRICOM TREATMENT GUIDELINES APPENDIX C: CENTCOM TREATMENT GUIDELINES APPENDIX D: EUCOM TREATMENT GUIDELINES APPENDIX E: INDOPACOM TREATMENT GUIDELINES APPENDIX F: NORTHCOM TREATMENT GUIDELINES APPENDIX G: SOUTHCOM TREATMENT GUIDELINES APPENDIX H: REGIONAL ANTIVENOM SELECTION FLOWCHARTS & ANTIVENOM DOSING BY PRODUCT APPENDIX I: CLASS VIII MEDICAL MATERIEL APPENDIX J: WHOLE BLOOD CLOTTING TEST APPENDIX K: METHODOLOGY FOR CLINICAL & OPERATIONAL UPDATES APPENDIX L: SNAKEBITE CPG DEVELOPMENT PROCESS APPENDIX M: FUTURE SNAKEBITE THERAPIES IN R&D PIPELINE APPENDIX N: FDA FORM 1572 APPENDIX O: REFERENCES APPENDIX P: TELEMEDICINE / TELECONSULTATION APPENDIX Q: INFORMATION REGARDING OFF-LABEL USES IN CPGS DOWNLOAD CPG IN PDF